Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | ARHGDIA | P52565 | 3/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13850442 | 0.95 | MAPK14 (0.43) | ROCK2ARHGDIAROCK1MAPK14LCK | |
| SCHEMBL13849294 | 0.83 | LCK (0.54) | ROCK2ARHGDIAROCK1MAPK14LCK | |
| SCHEMBL4090983 | 0.82 | MAPK14 (0.68) | MAPK14LCKFGFR1 | |
| SCHEMBL4097226 | 0.81 | LCK (0.52) | ROCK2ARHGDIAROCK1MAPK14LCK | |
| SCHEMBL4084679 | 0.80 | SIK2 (0.41) | MAPK14LCKSIK2FGFR1 | |
| SCHEMBL4084207 | 0.79 | MAPK14 (0.66) | MAPK14LCKFGFR1 | |
| SCHEMBL4084246 | 0.79 | LCK (0.42) | MAPK14LCKSIK2FGFR1 | |
| SCHEMBL13849310 | 0.79 | ROCK2 (0.50) | ROCK2ARHGDIAROCK1LTA4HOPRM1 | |
| SCHEMBL4084520 | 0.79 | MAPK14 (0.49) | ROCK2ARHGDIAROCK1MAPK14LCK | |
| SCHEMBL6335874 | 0.76 | MAPK14 (0.48) | MAPK14LCKSIK2SUV39H2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | claimed |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1831215-A1 | PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006056863-A1 | PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | TLR1, TPMT, NOD1 | ROCK2 844/4885ARHGDIA 1321/4885ROCK1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.